: iStockAnalyst.com Symbols Feed

Earnings Preview For Sep 28 - Oct 2 - Earnings Preview

Sat, 26 Sep 2009 05:03:14 GMT

Five S&P 500 companies are confirmed to report: Constellation Brands (STZ), Darden Restaurants (DRI), Jabil Circuit (JBL), Nike (NKE) and Walgreen (WAG). A total of 27 companies are on the calendar.[More...]

Biotech Industry Overview

Mon, 01 Jun 2009 14:38:59 GMT

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]

Biotech Industry - Industry Outlook

Thu, 16 Apr 2009 20:54:01 GMT

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]

Celera Drug Down to Sell - Analyst Blog

Thu, 19 Feb 2009 23:00:00 GMT

Q4 Financial Performance Falls Short of Expectations; '09 Outlook Bleak We downgrade Celera (CRA) shares from Hold to Sell based on the company's worse-than-expected calendar 4th quarter 2008 financial performance and bleak outlook for 2009. In the 4th quarter, ended December 31, 2008, total revenue was $47.3 million, compared to $40.3 million in the prior year quarter, up 17.4% year on year and 3.3% sequentially. The 4th quarter results in 2007 and 2008 included revenues from Berkeley HeartLab, Inc. (BHL) and Atria Genetics Inc., which were acquired during the 4th quarter of calendar 2007. Total revenue in calendar 4th quarter of 2008 was slightly short of our estimate of $48 million. Revenue by[More...]

EXBD Falling on Hard Times - Analyst Blog

Thu, 05 Feb 2009 21:37:00 GMT

Highlighted in this post are the following companies: Corporate Executive Board (EXBD), CRA International (CRAI), First Advantage Corporation (FADV) and Navigant Consulting (NCI). Shares of Sell-rated Corporate Executive Board (EXBD) are trading down 20% after releasing 4th-quarter results that fell short of Street expectations, and issuing a disappointing 2009 forecast. These results could be an ominous sign for other firms in the business consulting[More...]

New Preventive Medicine Index

Sun, 25 Jan 2009 18:49:00 GMT

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies[More...]

Analyst Comments: FactSet, Dean Foods, Jabil Circuit, CRA International, Broadcom, El Paso, Xilinx, Vodafone

Wed, 01 Oct 2008 12:49:00 GMT

FactSet Research Systems, Inc. (FDS) is a leading provider of global online integrated data-related products and services for the investment community (primarily bankers, investment managers and brokerage firms). The company combines information from more than 200 databases into its online service and provides tools to download and customize data for investment and portfolio analysis. FactSet generates revenue on a monthly subscription basis from its clients. FDS continues to demonstrate healthy growth as it expands internationally and enhances its offerings through strategic acquisitions. The company's flagship offering, Portfolio Manager Workstation (PMW) is a staple among asset managers. However, increasing competition from companies like S&P ([More...]

Analyst Comments: Verisign, Commerce Bancshares, Cyclacel Pharmaceuticals, Newmont, Ball Corp, Wendy, CRA International, Daimler

Wed, 03 Sep 2008 21:17:00 GMT

Verisign, Inc. (VRSN) reported $303 million in revenues during Q2, up 17.1% y/y but down 14.4% q/q. Revenues from core business (Domain Names, SSL Certificates, and Identity and Authentication Services (IAS), came in at $233 million. GAAP EPS came in at ($0.35) for the quarter. Pro-forma EPS of $0.25 exceeded our estimate by $0.03. Core business generated a non-GAAP operating margin of 34.2%, up from 30.3% registered in Q1 2008. Growth in the naming business slowed down. The management provided Q3 revenue guidance of $236-241 million. They remain confident of exiting 2008 with an operating margin of 35%. VeriSign is trading at 31.7 times our reduced 2008 earnings estimate of $0.98 per share. As the Internet spreads to mobile devices, we see VeriSign tapping this growth market with an array of value-added services. Moreover, we believe[More...]

IOSCO Releases New Credit Rating Agency Rules

Wed, 28 May 2008 17:33:27 GMT

Bloomberg reports:[More...]

Analyst Comments: Goodyear, Starwood Hotels, Celera, Ingram Micro, Xilinx, Telmex, Navigant, Safeway, Ford, RIO, Baidu.com, Select Comfort

Mon, 28 Apr 2008 18:27:10 GMT

The Goodyear Tire & Rubber Company (GT) is one of the largest tire manufacturing companies worldwide. Goodyear Tire is benefiting from a major restructuring program along with lower raw material costs and improved selling prices. However, weak tire volumes compel us to rate the shares a Hold with a target of $28.50. On April 25, 2008, Goodyear Tire & Rubber reported 2007...[More...]

Construction work slows beach drivers

Tue, 01 Dec 2009 16:47:00 GMT

Dec. 1--PANAMA CITY BEACH -- Panama City Beach drivers faced another traffic challenge Monday, with only a block separating the roadwork.
The alternative route included another construction zone, where traffic was down to one lane because of Panama City Beach's Community Redevelopment Area (CRA) project on South Thomas Drive.
The Joan Avenue-North Lagoon Drive intersection was closed unexpectedly Saturday after a water main break.

: iStockAnalyst.com Symbols Feed

Earnings Preview For Sep 28 - Oct 2 - Earnings Preview

Biotech Industry Overview

Biotech Industry - Industry Outlook

Celera Drug Down to Sell - Analyst Blog

EXBD Falling on Hard Times - Analyst Blog

New Preventive Medicine Index

Analyst Comments: FactSet, Dean Foods, Jabil Circuit, CRA International, Broadcom, El Paso, Xilinx, Vodafone

Analyst Comments: Verisign, Commerce Bancshares, Cyclacel Pharmaceuticals, Newmont, Ball Corp, Wendy, CRA International, Daimler

IOSCO Releases New Credit Rating Agency Rules

Analyst Comments: Goodyear, Starwood Hotels, Celera, Ingram Micro, Xilinx, Telmex, Navigant, Safeway, Ford, RIO, Baidu.com, Select Comfort

Construction work slows beach drivers

Delray hosts beach design workshop to get input for Beach Area Master Plan: Public input gathered for city's Beach Area Master Plan

Hollywood officials fire agency director amid outrage at beach fest's cost

Palmetto CRA Accepts Proposal for Land Sale

CRA: Some City-Owned Facilities Are a Mess

Mood Sours for BMC Land Deal

Delray Beach Commissioners Approve Plan for Affordable Housing: Approval Means the Developer Will Get $27 Million in Stimulus Money to Start Construction

Midwest BankCentre Bias? Data Suggest It, Coalition Says

Palmetto '10 Budget is $29.5 M

Two Homes on Poinsettia Face Demolition

Celera and Aurora Enter Collaboration for Use of Cardiovascular Genetics

Celera Corporation Reports Second Quarter 2009 Results

Celera Presents Data Replicating Its Immunodiagnostic Assay to Detect Lung Cancer from Blood Serum

StreetInvesting.Com Free Research on WNR, BLL, CRA, AAV, ICO and NOV

Celera Announces Preliminary Second Quarter 2009 Revenue Results

BenchmarkJournal.Com Free Analyst Review for SYY, UHS, UNM, TCO, MIL and CRA

Celera Grants License to Bayer Schering Pharma for Cancer-Related Targets

Celera to Webcast Presentation at the Eighth Annual Needham Life Sciences Conference on June 11, 2009

Celera to Webcast Presentation at the Eighth Annual JMP Securities Research Conference on May 18, 2009

Celera Corporation Reports First Quarter 2009 Results

Form 4 Milsten Scott For: Oct 30 (10K)

Form 4 Lee Victor For: Aug 12 (10K)

Form 4 Hall Christopher M For: Aug 12 (10K)

Form 4 DEBLASI UGO D For: Aug 12 (10K)

Form 4 ARATA PAUL D For: Aug 12 (10K)

Form 4 ORDONEZ KATHY For: Aug 12 (10K)

Form 4 Milsten Scott For: Aug 12 (10K)

Form 4 SIAS STACEY R For: Aug 12 (10K)

Form 4 WHITE THOMAS J For: Aug 12 (10K)

Form 4 ZOCCOLI MICHAEL A. For: Aug 12 (10K)